http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-199800399-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24 |
| filingDate | 1996-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1998-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-199800399-A1 |
| titleOfInvention | SULPHATE CONJUGATES OF URSODEZOXYCHOLIC ACID AND THEIR APPLICATION IN MEDICAL PURPOSES IN INFLAMMATORY DISEASES AND OTHER CASES |
| abstract | The invention in one of its aspects is directed to the creation of a pharmacologically acceptable composition comprising 3α, 7β-dihydroxy-5β-cholan-24-oic acid sulfate ("ursodeoxycholic acid", or UDCA), as well as its pharmacologically acceptable carrier. In a preferred composition of the invention, the sulfate is UDCA-3-sulfate, UDCA-7-sulfate, UDCA-3,7-disulfate, glyco-UDCA-3-sulfate, glyco-UDCA-7-sulfate, glyco-UDCA-3, 7-disulfate, tauro-UDHK-3-sulfate, tauro-UDHK-7-sulfate, tauro-UDCA-3,7-disulfate, or a combination of these. In another aspect, the invention relates to a method of delivering UDCA to a mammal in order to suppress or cure a disease, which includes administering UDCA sulphate to a mammal in an amount sufficient to suppress or cure the disease. For example, sulfate, UDCA may be effectively used in the suppression or treatment of an inflammatory condition of the gastrointestinal tract, such as colon cancer, rectal cancer, neoplasm of the colon, neoplasm of the rectum, carcinogenesis of the colon, carcinogenesis of the rectum, ulcerative colitis, adenomatous polyp , family polyposis, etc. UDCA sulfate may also be administered to suppress or treat inflammatory liver disease. UDCA sulfate can be used to improve serum biochemistry of renal disease or renal function, to increase the flow of bile, or to reduce the biliary secretion of phospholipid or cholesterol. Another aspect of the invention relates to the creation of a method of preserving an isolated organ by perfusing this organ with UDCA sulfate. The international search report published 1997.06.26. |
| priorityDate | 1995-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 30.